GT200900154A - Derivados de 2,3-dihidroimidozo [1,2-c] quinizolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis - Google Patents
Derivados de 2,3-dihidroimidozo [1,2-c] quinizolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesisInfo
- Publication number
- GT200900154A GT200900154A GT200900154A GT200900154A GT200900154A GT 200900154 A GT200900154 A GT 200900154A GT 200900154 A GT200900154 A GT 200900154A GT 200900154 A GT200900154 A GT 200900154A GT 200900154 A GT200900154 A GT 200900154A
- Authority
- GT
- Guatemala
- Prior art keywords
- treatment
- angiogenesis
- hyperproliferative disorders
- quinizolina
- dihydroimidozo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
- A01N43/54—1,3-Diazines; Hydrogenated 1,3-diazines
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Plant Pathology (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
Abstract
NUEVOS COMPUESTOS DE 2,3-DIHIDROIMIDAZO (1,2-C) QUINAZOLINA, CON COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN A DICHOS COMPUESTOS Y CON EL USO DE DICHOS COMPUESTOS O COMPOSICIONES EN LA INHIBICIÓN Y EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON LA ACTIVIDAD DE LA FOSFOTIDILINOSITOL-3-QUINASA (PI3K), EN PARTICULAR EN EL TRATAMIENTO DE TRASTORNOS HIPERPROLIFERATIVOS Y/O DE ANGIOGÉNESIS, COMO AGENTE ÚNICO O EN COMBINACIÓN CON OTROS INGREDIENTES ACTIVOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87309006P | 2006-12-05 | 2006-12-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT200900154A true GT200900154A (es) | 2012-01-17 |
Family
ID=39492563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200900154A GT200900154A (es) | 2006-12-05 | 2009-06-05 | Derivados de 2,3-dihidroimidozo [1,2-c] quinizolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis |
Country Status (42)
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5620275B2 (ja) * | 2008-01-14 | 2014-11-05 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 超増殖性疾患及び脈管形成に関連する疾病を処理するために有用なスルホン置換された2,3−ジヒドロイミダゾ[1,2−c]キナゾリン誘導体類 |
EP2168583A1 (en) * | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
EP2168582A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
CA2735932C (en) * | 2008-09-30 | 2013-07-09 | Pfizer Inc. | Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions |
EP2184276A1 (en) | 2008-11-07 | 2010-05-12 | Universite Paul Cezanne Aix-Marseille Iii | Process to prepare new substituted 1H-Benzo(d) imidazol-2(3h)-Ones, New intermediates and their use as bace 1 inhibitors |
WO2010082627A1 (ja) | 2009-01-16 | 2010-07-22 | ダイソー株式会社 | 2-ヒドロキシメチルモルホリン塩の製造方法 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
CA2796253A1 (en) | 2010-04-16 | 2011-10-20 | Bayer Intellectual Property Gmbh | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
US20130197043A1 (en) | 2010-08-31 | 2013-08-01 | Snu R&Db Foundation | Use of the fetal reprogramming of a ppar agonist |
UA113280C2 (xx) * | 2010-11-11 | 2017-01-10 | АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ | |
ES2639402T3 (es) * | 2010-11-11 | 2017-10-26 | Bayer Intellectual Property Gmbh | 2,3-dihidroimidazo[1,2-c]quinolinas sustituidas con arilaminoalcohol |
WO2012062745A1 (en) | 2010-11-11 | 2012-05-18 | Bayer Pharma Aktiengesellschaft | Alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
JO3733B1 (ar) * | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US9789193B2 (en) | 2012-06-15 | 2017-10-17 | The Brigham And Women's Hospital, Inc. | Compositions for treating cancer and methods for making the same |
EP2914260A1 (en) | 2012-10-31 | 2015-09-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
BR112015009879A8 (pt) * | 2012-11-02 | 2019-09-17 | Lab Francais Du Fractionnement | método in vitro de inibição da proliferação de uma população de células, composto, kit e composição farmacêutica |
CN103214489B (zh) * | 2013-02-25 | 2016-10-26 | 中国人民解放军第二军医大学 | 一类具有抗肿瘤活性的多靶点激酶抑制剂及其制备方法 |
UA122822C2 (uk) * | 2013-04-08 | 2021-01-06 | Байєр Фарма Акцієнгезелльшафт | ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ |
CN104557955B (zh) * | 2013-10-23 | 2017-05-03 | 上海汇伦生命科技有限公司 | 作为PI3K/mTOR抑制剂的三环类化合物,其制备方法和用途 |
CA2931615A1 (en) * | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
US10124007B2 (en) | 2013-12-03 | 2018-11-13 | Bayer Pharma Aktiengesellschaft | Combination of PI3K-inhibitors |
CA2932221C (en) * | 2013-12-03 | 2022-02-22 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
TWI533869B (zh) | 2014-03-11 | 2016-05-21 | 國立中央大學 | 蒽醌[2,1-c][1,2,5]噻二唑-6,11-二酮化合物緩解疼痛的應用 |
TWI533871B (zh) | 2014-03-11 | 2016-05-21 | 國立中央大學 | 萘并[2,3-f]喹喔啉-7,12-二酮化合物緩解疼痛的應用 |
FR3018813B1 (fr) * | 2014-03-18 | 2016-04-15 | Maco Pharma Sa | Procede de synthese d'un derive de psoralene |
WO2016059220A1 (en) | 2014-10-16 | 2016-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tcr-activating agents for use in the treatment of t-all |
EP3018127A1 (en) * | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
EP3018131A1 (en) * | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
CA2978830A1 (en) | 2015-03-09 | 2016-09-15 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
CA2978807A1 (en) * | 2015-03-09 | 2016-09-15 | Bayer Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
FR3033499A1 (fr) * | 2015-03-11 | 2016-09-16 | Centre Leon-Berard | Composition pour le traitement des tumeurs neuroendocrines pancreatiques |
SG10201913980SA (en) * | 2015-07-02 | 2020-03-30 | Hoffmann La Roche | Benzoxazepin oxazolidinone compounds and methods of use |
CN105130998B (zh) * | 2015-09-25 | 2017-07-28 | 苏州立新制药有限公司 | 库潘尼西的制备方法 |
CN105130997B (zh) * | 2015-09-25 | 2017-12-05 | 苏州明锐医药科技有限公司 | 一种库潘尼西的制备方法 |
US10844066B2 (en) | 2016-03-08 | 2020-11-24 | Bayer Pharma Aktiengesellschaft | 2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides |
EP3219329A1 (en) | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
JP7079937B2 (ja) * | 2016-05-26 | 2022-06-03 | ユニバーシティ オブ ピッツバーグ -オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 肺血管疾患を治療するための組成物および方法 |
CN108368117B (zh) * | 2016-06-08 | 2021-03-02 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的咪唑并喹唑啉化合物及其药物组合物 |
US10925880B2 (en) | 2016-09-23 | 2021-02-23 | Bayer Pharma Aktiengesellschaft | Combination of PI3K-inhibitors |
CN106177918A (zh) * | 2016-09-30 | 2016-12-07 | 广州赛莱拉干细胞科技股份有限公司 | 一种间充质干细胞注射液及其制备方法和应用 |
WO2018112176A1 (en) | 2016-12-14 | 2018-06-21 | Tarveda Therapeutics, Inc. | Hsp90-targeting conjugates and formulations thereof |
EP3585437B1 (en) | 2017-02-24 | 2022-12-21 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib with anti-pd-1 antibody |
WO2018215282A1 (en) | 2017-05-26 | 2018-11-29 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and pi3k inhibitors |
WO2019002068A1 (en) | 2017-06-28 | 2019-01-03 | Bayer Consumer Care Ag | COMBINATION OF A PI3K INHIBITOR AND AN ANDROGEN RECEPTOR ANTAGONIST |
US11253594B2 (en) * | 2017-07-07 | 2022-02-22 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Drug combinations for protecting against neuronal cell death |
JP6916562B2 (ja) * | 2017-08-11 | 2021-08-11 | テリジーン リミテッドTeligene Ltd. | 化合物、その薬学的に許容される塩、溶媒和物、立体異性体及び互変異性体、並びに薬物組成物、過剰増殖性障害治療剤、過剰増殖性障害予防剤、薬物、癌治療剤、癌予防剤、及びキナーゼシグナル伝達調節剤 |
EP3498266A1 (en) | 2017-12-15 | 2019-06-19 | Bayer Consumer Care AG | Formulations of copanlisib |
IL272857B2 (en) | 2017-09-08 | 2024-03-01 | Bayer Consumer Care Ag | Cofanalisib formulations |
WO2019105734A1 (en) | 2017-11-28 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib |
WO2019105835A1 (en) | 2017-11-29 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib and anetumab ravtansine |
WO2019197269A1 (en) | 2018-04-11 | 2019-10-17 | Bayer Aktiengesellschaft | Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer |
CN108383849B (zh) * | 2018-04-26 | 2020-11-06 | 浙江大学 | 咪唑并喹唑啉衍生物及其在抗肿瘤抗炎中的应用 |
CN108841318A (zh) * | 2018-07-12 | 2018-11-20 | 中国科学院海洋研究所 | 一种自修复壳聚糖水凝胶防腐涂料及其合成方法 |
US20210187134A1 (en) | 2018-08-28 | 2021-06-24 | Bayer As | Combination of pi3k-inhibitors and targeted thorium conjugates |
EP3866805A1 (en) | 2018-10-16 | 2021-08-25 | Bayer Aktiengesellschaft | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds |
CN109516961B (zh) * | 2018-12-25 | 2021-01-01 | 浙江大学 | 氨基喹唑啉酮和氨基异喹啉酮衍生物及其应用 |
WO2020164997A1 (en) | 2019-02-12 | 2020-08-20 | Bayer Aktiengesellschaft | Combination of pi3k-inhibitors |
WO2023139125A1 (en) | 2022-01-18 | 2023-07-27 | Synthon B.V. | Improved process for preparation of copanlisib |
WO2023218032A1 (en) | 2022-05-13 | 2023-11-16 | Synthon B.V. | Solid forms of copanlisib salts |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3644354A (en) | 1968-09-16 | 1972-02-22 | Sandoz Ag | 5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines |
US4146718A (en) | 1978-04-10 | 1979-03-27 | Bristol-Myers Company | Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
AU2001252609A1 (en) * | 2000-04-27 | 2001-11-12 | Imperial Cancer Research Technology Ltd. | Imidazopyridine derivatives |
PA8578001A1 (es) * | 2002-08-07 | 2004-05-07 | Warner Lambert Co | Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas |
UA82205C2 (en) * | 2002-09-30 | 2008-03-25 | Байер Фармасьютикалз Корпорейшн | Fused azole-pyrimidine derivatives |
AT412873B (de) | 2004-02-20 | 2005-08-25 | Aop Orphan Pharmaceuticals Ag | Verfahren zur herstellung von anagrelid hydrochlorid |
WO2007143483A2 (en) | 2006-06-01 | 2007-12-13 | Smithkline Beecham Corporation | Combination of pazopanib and lapatinib for treating cancer |
WO2008002039A1 (en) | 2006-06-28 | 2008-01-03 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives for inhibiting the growth of cancer cell |
EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
-
2007
- 2007-12-03 AR ARP070105390A patent/AR064106A1/es active IP Right Grant
- 2007-12-04 UY UY30761A patent/UY30761A1/es not_active Application Discontinuation
- 2007-12-04 PE PE2007001709A patent/PE20081444A1/es active IP Right Grant
- 2007-12-04 JO JOP/2007/0517A patent/JO3147B1/ar active
- 2007-12-04 TW TW096145999A patent/TWI406662B/zh active
- 2007-12-04 PA PA20078759601A patent/PA8759601A1/es unknown
- 2007-12-05 US US15/398,916 patent/USRE46856E1/en active Active
- 2007-12-05 WO PCT/US2007/024985 patent/WO2008070150A1/en active Application Filing
- 2007-12-05 UA UAA200906701A patent/UA96965C2/ru unknown
- 2007-12-05 CN CN202211453281.7A patent/CN115724847A/zh active Pending
- 2007-12-05 EP EP07862580.3A patent/EP2096919B1/en active Active
- 2007-12-05 DK DK07862580.3T patent/DK2096919T3/en active
- 2007-12-05 PL PL07862580T patent/PL2096919T3/pl unknown
- 2007-12-05 NZ NZ577342A patent/NZ577342A/en unknown
- 2007-12-05 KR KR1020097011551A patent/KR101501785B1/ko active IP Right Grant
- 2007-12-05 CN CN200780044849.7A patent/CN101631464B/zh active Active
- 2007-12-05 MX MX2009006001A patent/MX2009006001A/es active IP Right Grant
- 2007-12-05 US US12/517,875 patent/US8466283B2/en not_active Ceased
- 2007-12-05 ES ES07862580T patent/ES2572189T3/es active Active
- 2007-12-05 CN CN201810535933.9A patent/CN108774232B/zh active Active
- 2007-12-05 SI SI200731771A patent/SI2096919T1/sl unknown
- 2007-12-05 HU HUE07862580A patent/HUE028773T2/en unknown
- 2007-12-05 BR BRPI0720178A patent/BRPI0720178B8/pt active IP Right Grant
- 2007-12-05 CL CL200703508A patent/CL2007003508A1/es unknown
- 2007-12-05 AU AU2007328008A patent/AU2007328008B2/en active Active
- 2007-12-05 RS RS20170561A patent/RS56045B1/sr unknown
- 2007-12-05 CA CA2671614A patent/CA2671614C/en active Active
- 2007-12-05 MY MYPI20092044A patent/MY157944A/en unknown
- 2007-12-05 CN CN201510632842.3A patent/CN105254634B/zh active Active
- 2007-12-05 EA EA200900733A patent/EA018839B1/ru not_active IP Right Cessation
- 2007-12-05 SG SG2011088887A patent/SG177170A1/en unknown
- 2007-12-05 JP JP2009540293A patent/JP5326092B2/ja active Active
-
2009
- 2009-04-13 TN TNP2009000137A patent/TN2009000137A1/fr unknown
- 2009-04-21 IL IL198273A patent/IL198273A/en active IP Right Grant
- 2009-06-04 HN HN2009001131A patent/HN2009001131A/es unknown
- 2009-06-04 EC EC2009009387A patent/ECSP099387A/es unknown
- 2009-06-04 CO CO09057915A patent/CO6220908A2/es active IP Right Grant
- 2009-06-05 SV SV2009003288A patent/SV2009003288A/es unknown
- 2009-06-05 DO DO2009000135A patent/DOP2009000135A/es unknown
- 2009-06-05 CU CU20090103A patent/CU23796B7/es active IP Right Grant
- 2009-06-05 CR CR10838A patent/CR10838A/es unknown
- 2009-06-05 GT GT200900154A patent/GT200900154A/es unknown
- 2009-06-29 MA MA32057A patent/MA31283B1/fr unknown
- 2009-07-03 ZA ZA200904691A patent/ZA200904691B/xx unknown
- 2009-07-03 NO NO20092529A patent/NO342348B1/no unknown
-
2013
- 2013-06-03 US US13/908,566 patent/US20130261113A1/en not_active Abandoned
-
2016
- 2016-05-26 HK HK16106013.2A patent/HK1217953A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200900154A (es) | Derivados de 2,3-dihidroimidozo [1,2-c] quinizolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis | |
CU20130069A7 (es) | Derivados de 2,3-dihidroimidazo[1,2-c] quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermeddes asociadas a la angiogénesis | |
UY31080A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis | |
WO2009091550A3 (en) | Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis | |
MY143795A (en) | Tetrahydropyridoindole derivatives | |
PA8748101A1 (es) | Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus | |
UY31079A1 (es) | Derivados de fenilaminobenceno sustituidos de utilidad para el tratamiento de trastornos y enfermedades hiperproliferativos asociados con actividad quinasa extracelular mediada por mitógenos | |
DE602005021770D1 (de) | Indol-1-yl-essigsäurederivate | |
ECSP034916A (es) | Oxazolidinonas substituidas para terapia de combinacion | |
CU23208A3 (es) | Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea | |
CL2008001721A1 (es) | Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales. | |
UY37149A (es) | 2–amino–n–[7–metoxi–2,3–dihidroimidazo–[1,2–c]quinazolin–5–il]pirimidin–5–carboxamidas | |
ATE410424T1 (de) | Spirocyclische cyclohexan-derivate | |
UA110013C2 (uk) | Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів | |
UY28366A1 (es) | Compuestos químicos | |
BRPI0409878A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
BRPI0510503A (pt) | compostos e composições como inibidores de catepsina s | |
HK1135694A1 (en) | Imino-imidazo-pyridine derivatives having antithrombotic activity | |
CY1117512T1 (el) | Υποκατεστημενα παραγωγα 2,3-δiυδpoϊmiδazo[1,2-c] κιναζολινης χρησιμα στη θεραπευτικη αντιμετωπιση υπερ-πολλαπλασιαστικων διαταραχων και παθησεων που σχετιζονται με την αγγειογενεση | |
TNSN06068A1 (en) | Pharmaceutical composition containing in association ubidecarenone, dexpanthenol and chlorhexidine or a pharmaceutically acceptable salt thereof for cutaneous application | |
PL1700597T3 (pl) | Kompozycja farmaceutyczna do podawania na skórę, zawierająca łącznie ubidekarenon, despantenol oraz chlorheksydynę lub jej farmakologicznie dopuszczalną sól |